Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab, Cetuximab, and Irinotecan in Advanced Right-Sided Colon Cancer
NCT07896681Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in colon cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 24 months. Started Jul 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07896681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896681.